For research use only. Not for therapeutic Use.
FR-229934 is a PDE V inhibitor extracted from patent WO2019130052A1. FR-229934 can be used for the research of pulmonary arterial hypertension and erectile dysfunction[1].
| Catalog Number | I006885 |
| CAS Number | 799841-02-4 |
| Synonyms | 3-[(3,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide |
| Molecular Formula | C21H23Cl2N3O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C21H23Cl2N3O3S/c1-3-4-5-10-30(28,29)25-21(27)16-7-9-19-20(12-16)26(14(2)24-19)13-15-6-8-17(22)18(23)11-15/h6-9,11-12H,3-5,10,13H2,1-2H3,(H,25,27) |
| InChIKey | QLXVZAXTUBLQJW-UHFFFAOYSA-N |
| SMILES | CCCCCS(=O)(=O)NC(=O)C1=CC2=C(C=C1)N=C(N2CC3=CC(=C(C=C3)Cl)Cl)C |
| Reference | [1]. PANDYA J, et, al. Liquid oral formulations for pde v inhibitors. WO2019130052A1. |
